# Paroxysmal Supraventricular Tachycardia Market

> Paroxysmal Supraventricular Tachycardia (PSVT) Market: by Type (AVNRT, AVRT, PAT, WPW) Diagnosis (EPS, Echocardiogram, Holter Monitor, Event Monitor) Treatment (Physical Maneuvers, medications), End-User (Hospitals & Clinics) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.89%
- **2024:** $ 299.29 Million
- **2025:** $ 319.91 Million
- **2035:** $ 622.88 Million
- **Key Players:** Abbott Laboratories (US), Medtronic (US), Boston Scientific (US), Johnson & Johnson (US), Bayer AG (DE), Bristol-Myers Squibb (US), AstraZeneca (GB), Cardinal Health (US), Stryker Corporation (US)

**Report ID:** MRFR/MED/4462-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/paroxysmal-supraventricular-tachycardia-market-5918

---

## Market Summary

## **Paroxysmal Supraventricular Tachycardia (PSVT) Market Scenario**

Paroxysmal Supraventricular Tachycardia Market Size was valued at USD 0.28 Billion in 2023. The Paroxysmal Supraventricular Tachycardia industry is projected to grow from USD 0.30 Billion in 2024 to USD 0.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.30% during the forecast period (2024 - 2032). Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating.

People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.

The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.

The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.

**Intended Audience**

**Figure 1: Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, by Region**

## **Paroxysmal Supraventricular Tachycardia (PSVT) Market Segmentation**

The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), [Paroxysmal Atrial Tachycardia](../../../reports/paroxysmal-atrial-tachycardia-market-4910) (PAT), and Wolff-Parkinson-White Syndrome (WPW).

On the basis of diagnosis, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, [cardiac catheterization](../../../reports/cardiac-catheterization-market-972), coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.

On the basis of treatment, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, [pacemaker](../../../reports/pacemaker-market-1587), and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.

On the basis of end-user, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.

**Research Methodology**

Sources: Annual reports, Press release, White paper, and Company presentation

## **Paroxysmal Supraventricular Tachycardia (PSVT) Market Regional Analysis**

The Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.

Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.

The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of paroxysmal supraventricular tachycardia market.

## **Paroxysmal Supraventricular Tachycardia (PSVT) Market Key Players**

Some of the key players in the Paroxysmal Supraventricular Tachycardia (PSVT) market are: 

## Market Drivers

### Aging Population

The demographic shift towards an aging population is a significant driver of the Global Paroxysmal Supraventricular Tachycardia Market (PSVT) Market Industry. Older adults are more susceptible to cardiovascular conditions, including PSVT, due to age-related physiological changes. As the global population ages, the incidence of PSVT is likely to rise, leading to increased demand for treatment options. This trend is particularly evident in developed countries, where healthcare systems are adapting to cater to the needs of older patients. Consequently, the market is poised for growth as healthcare providers focus on managing PSVT in this demographic.

### Rising Incidence of PSVT

The Global Paroxysmal Supraventricular Tachycardia Market (PSVT) Market Industry is witnessing a notable increase in the incidence of PSVT, driven by factors such as lifestyle changes and increased stress levels. As more individuals experience episodes of rapid heart rate, the demand for effective treatment options rises. In 2024, the market is valued at approximately 0.3 USD Billion, reflecting the growing awareness and diagnosis of this condition. This trend is expected to continue, with projections indicating a market value of 0.62 USD Billion by 2035, suggesting a robust growth trajectory fueled by the rising prevalence of PSVT.

### Market Growth Projections

The Global Paroxysmal Supraventricular Tachycardia Market (PSVT) Market Industry is projected to experience substantial growth over the next decade. With a market valuation of 0.3 USD Billion in 2024, it is expected to reach 0.62 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.89% from 2025 to 2035. This growth is indicative of the increasing recognition of PSVT as a significant health issue and the corresponding demand for effective treatment options. The market dynamics suggest a favorable environment for stakeholders, including healthcare providers and pharmaceutical companies, to engage in the development and distribution of PSVT therapies.

### Increased Awareness and Diagnosis

There is a growing awareness regarding cardiovascular diseases, including PSVT, which is positively influencing the Global Paroxysmal Supraventricular Tachycardia Market (PSVT) Market Industry. Public health campaigns and educational initiatives are helping to inform both healthcare professionals and patients about the symptoms and risks associated with PSVT. This heightened awareness leads to earlier diagnosis and treatment, which is essential for effective management of the condition. As a result, the market is expected to see substantial growth, with a projected compound annual growth rate (CAGR) of 6.89% from 2025 to 2035, indicating a sustained interest in addressing this health concern.

### Advancements in Treatment Modalities

Innovations in medical technology are significantly impacting the Global Paroxysmal Supraventricular Tachycardia Market (PSVT) Market Industry. New treatment modalities, including catheter ablation and advanced antiarrhythmic drugs, are emerging, offering patients more effective and less invasive options. These advancements not only enhance patient outcomes but also contribute to the overall growth of the market. The introduction of novel therapies is likely to attract more patients seeking relief from PSVT symptoms, thereby expanding the market. As the industry evolves, it is anticipated that these innovations will play a crucial role in shaping the future landscape of PSVT treatment.

### Regulatory Support for New Therapies

Regulatory bodies are increasingly supportive of the development and approval of new therapies for PSVT, which is fostering growth in the Global Paroxysmal Supraventricular Tachycardia Market (PSVT) Market Industry. Streamlined approval processes and incentives for innovation are encouraging pharmaceutical companies to invest in research and development of novel treatment options. This regulatory environment not only accelerates the availability of new therapies but also enhances competition within the market. As a result, patients benefit from a wider array of treatment choices, which is likely to drive market expansion in the coming years.

## Future Outlook

The Paroxysmal Supraventricular Tachycardia Market is projected to grow at a 6.89% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence, and enhanced treatment options.

**New opportunities:**

- Development of wearable cardiac monitoring devices for real-time data collection. Expansion of telehealth services for remote patient management and follow-up. Investment in AI-driven analytics for personalized treatment plans and outcomes.

By 2035, the market is expected to exhibit robust growth, driven by innovation and increased patient engagement.

## Segment Insights

### By Type of Paroxysmal Supraventricular Tachycardia: Atrioventricular Nodal Reentrant Tachycardia (Largest) vs. Atrial Tachycardia (Fastest-Growing)

The Paroxysmal Supraventricular Tachycardia (PSVT) market showcases a diverse landscape of segment values, with Atrioventricular Nodal Reentrant Tachycardia leading the charge as the largest segment due to its prevalence in the population. This condition accounts for a significant share of PSVT cases, making it a focal point for both clinical attention and market investments. In contrast, Atrial Tachycardia is emerging rapidly, with increased recognition and advancements in treatment options driving its growth in recent years. As healthcare providers refine their approaches to managing PSVT, the dynamics among these segments evolve, reflecting shifts in clinical practice and patient awareness.

Atrioventricular Nodal Reentrant Tachycardia (Dominant) vs. Atrial Tachycardia (Emerging)

Atrioventricular Nodal Reentrant Tachycardia (AVNRT) is recognized as the dominant form of paroxysmal supraventricular tachycardia, characterized by its typical presentation and established treatment pathways, thus commanding a substantial share of market attention. AVNRT is often effectively managed through ablation techniques, which have improved patient outcomes significantly. On the other hand, Atrial Tachycardia is becoming an important emerging segment, gaining traction as awareness increases around different tachycardia types. Atrial Tachycardia is known for its variable characteristics and, while less common than AVNRT, it is witnessing a faster growth rate due to advancements in diagnostic technologies and therapeutic options, positioning it uniquely in the evolving market landscape.

### By Treatment Approach: Medication (Largest) vs. Catheter Ablation (Fastest-Growing)

In the Paroxysmal Supraventricular Tachycardia Market, the treatment approach is diverse, with 'Medication' holding the largest share. This category includes various antiarrhythmic drugs that have proven effective in managing symptoms and reducing episodes. In contrast, 'Catheter Ablation' stands out as the fastest-growing segment, driven by advancements in technology and an increasing preference for minimally invasive procedures among patients and healthcare providers. As patients look for more sustainable treatment options, these segments indicate a shifting landscape in treatment preferences. The growth trends in the 'Treatment Approach' segment are influenced by factors such as an aging population, increased awareness of heart rhythm disorders, and technological innovations in catheter ablation techniques. Medication usage remains prevalent due to its ease of administration and established efficacy, while catheter ablation is experiencing rapid adoption due to its potential for long-term cures. As physicians and patients continue to navigate treatment options, the emphasis on personalized approaches is likely to define future developments in this market.

Medication (Dominant) vs. Catheter Ablation (Emerging)

The 'Medication' segment is characterized by a wide range of antiarrhythmic drugs that are integral to managing Paroxysmal Supraventricular Tachycardia. This approach is traditionally viewed as the first line of treatment, offering a non-invasive solution for symptom control. On the other hand, 'Catheter Ablation' is an emerging treatment option that involves mapping and destroying the specific areas of the heart causing the abnormal electrical signals. As technology evolves, catheter ablation is becoming increasingly favored due to its potential for providing a permanent solution to the arrhythmia. Patients looking for effective long-term management find catheter ablation appealing, positioning it as a notable contender against established medication therapies.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Paroxysmal Supraventricular Tachycardia (PSVT) market, the age group segment holds a substantial share, indicating a higher prevalence of PSVT incidents among older adults. Younger demographics also contribute to the market, but they represent a smaller fraction of the patients diagnosed. The male to female ratio in PSVT cases displays varied distribution, typically leaning towards males, which aligns with observed trends in cardiovascular conditions across different age groups.

Age Group: 60+ (Dominant) vs. Gender: Female (Emerging)

In the patient demographics for PSVT, individuals aged 60 and above are recognized as the dominant age group, primarily due to age-related physiological changes that increase the risk of tachyarrhythmias. Meanwhile, the female patient demographic is emerging as a significant segment, driven by rising awareness and diagnosis rates among women suffering from cardiovascular issues. The inclusion of women patients into clinical studies and marketing strategies highlights a growing understanding of PSVT's impact on diverse populations, emphasizing tailored approaches to treatment and management.

### By Diagnosis Method: Electrocardiogram (Largest) vs. Holter Monitor (Fastest-Growing)

The Paroxysmal Supraventricular Tachycardia (PSVT) market is significantly influenced by the various diagnosis methods, with the Electrocardiogram (ECG) leading the segment due to its widespread accessibility and effectiveness in detecting arrhythmias promptly. Holter Monitor follows closely as it provides extended monitoring, offering a significant advantage for diagnosing intermittent conditions like PSVT. The Event Monitor and Electrophysiological Study, while essential, hold a smaller market share but are critical when patients exhibit atypical symptoms leading to further investigation.

Diagnosis Methods: ECG (Dominant) vs. Electrophysiological Study (Emerging)

The Electrocardiogram (ECG) remains the dominant diagnostic method in the PSVT market due to its efficiency and immediate results in identifying tachycardia episodes. Its simplicity and quick turnaround time position it as the first-line diagnostic tool. Conversely, the Electrophysiological Study, though less commonly performed, is emerging as a vital method for patients with complex cases. This invasive procedure allows for in-depth analysis and can guide targeted therapeutic strategies. As technology improves, the Electrophysiological Study is gaining traction, becoming crucial for tailored patient management.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Paroxysmal Supraventricular Tachycardia market, holding a significant market share of $149.65M in 2024. The region's growth is driven by increasing prevalence of cardiovascular diseases, advancements in medical technology, and supportive regulatory frameworks. The demand for effective treatment options is further fueled by rising healthcare expenditures and a focus on patient-centric care. The competitive landscape in North America is robust, featuring key players such as Abbott Laboratories, Medtronic, and Boston Scientific. These companies are at the forefront of innovation, developing cutting-edge therapies and devices. The U.S. remains the largest market, supported by a well-established healthcare infrastructure and a high rate of adoption of new technologies. This dynamic environment is expected to foster continued growth in the coming years.

### Europe : Emerging Market with Potential

Europe is witnessing a growing market for Paroxysmal Supraventricular Tachycardia, with a market size of €85.0M. The region's growth is driven by an aging population, increasing awareness of cardiovascular health, and advancements in treatment options. Regulatory bodies are actively promoting innovative therapies, which is expected to enhance patient access to effective treatments and improve health outcomes across member states. Leading countries in Europe include Germany, France, and the UK, where significant investments in healthcare infrastructure are being made. The competitive landscape features major players like Bayer AG and Bristol-Myers Squibb, who are focusing on research and development to introduce novel therapies. The European market is characterized by a mix of established companies and emerging startups, creating a vibrant ecosystem for innovation.

### Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is experiencing significant growth in the Paroxysmal Supraventricular Tachycardia market, valued at $50.0M. This growth is attributed to increasing healthcare investments, rising awareness of cardiovascular diseases, and a growing middle-class population seeking advanced medical solutions. Regulatory bodies are also enhancing frameworks to facilitate the introduction of innovative therapies, which is expected to drive market expansion further. Countries like China, Japan, and India are leading the charge in this region, with a focus on improving healthcare access and quality. The competitive landscape is evolving, with both global and local players, including Johnson & Johnson and AstraZeneca, actively participating. The presence of a diverse range of treatment options is expected to cater to the varying needs of patients across different markets in the region.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Paroxysmal Supraventricular Tachycardia market, currently valued at $14.64M. Growth is driven by increasing healthcare investments and a rising prevalence of cardiovascular diseases. However, challenges such as regulatory hurdles and limited access to advanced medical technologies can impede market growth. Efforts are being made to improve healthcare infrastructure and regulatory frameworks to enhance patient access to treatments. Leading countries in this region include South Africa and the UAE, where healthcare reforms are being implemented to attract investments. The competitive landscape is characterized by a mix of local and international players, with companies like Cardinal Health and Stryker Corporation making strides in the market. The focus on improving healthcare delivery systems is expected to create new opportunities for growth in the coming years.

## Competitive Benchmarking

The Paroxysmal Supraventricular Tachycardia Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and advancements in treatment modalities. Key players such as Abbott Laboratories (US), Medtronic (US), and Boston Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott Laboratories (US) focuses on innovation through the development of advanced cardiac monitoring devices, while Medtronic (US) emphasizes strategic partnerships to expand its product offerings. Boston Scientific (US) is actively pursuing mergers and acquisitions to bolster its portfolio, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly characterized by technological advancements and collaborative efforts.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they leverage their resources to drive innovation and improve patient outcomes. This competitive structure suggests that while there is room for smaller entrants, the dominance of established players is likely to shape market dynamics significantly.
In November Abbott Laboratories (US) announced the launch of a new cardiac monitoring system designed to provide real-time data to healthcare providers. This strategic move is expected to enhance patient management and improve treatment outcomes, reflecting the company's commitment to innovation in cardiac care. The introduction of such technology may also position Abbott as a leader in the digital health space, potentially attracting a broader patient base.
In October Medtronic (US) entered into a partnership with a leading telehealth provider to integrate remote monitoring capabilities into its existing cardiac devices. This collaboration is indicative of a growing trend towards digital health solutions, allowing for more personalized patient care. By enhancing its product offerings through telehealth integration, Medtronic is likely to strengthen its competitive edge in the market.
In September Boston Scientific (US) completed the acquisition of a smaller medical device company specializing in atrial fibrillation treatments. This acquisition not only expands Boston Scientific's product portfolio but also enhances its capabilities in addressing a broader range of cardiac conditions. Such strategic actions suggest a proactive approach to market consolidation, enabling Boston Scientific to leverage synergies and improve its market position.
As of December current competitive trends in the Paroxysmal Supraventricular Tachycardia Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive landscape is shifting from traditional price-based competition to a focus on technological advancements and supply chain reliability. This evolution indicates that future differentiation will likely hinge on the ability to deliver innovative solutions that enhance patient care and operational efficiency.

## Report Scope

| MARKET SIZE 2024 | 299.29(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 319.91(USD Million) |
| MARKET SIZE 2035 | 622.88(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.89% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Medtronic (US), Boston Scientific (US), Johnson & Johnson (US), Bayer AG (DE), Bristol-Myers Squibb (US), AstraZeneca (GB), Cardinal Health (US), Stryker Corporation (US) |
| Segments Covered | Type of Paroxysmal Supraventricular Tachycardia, Treatment Approach, Patient Demographics, Diagnostic Method |
| Key Market Opportunities | Advancements in catheter ablation techniques enhance treatment options in the Paroxysmal Supraventricular Tachycardia Market. |
| Key Market Dynamics | Rising demand for innovative treatment options drives competitive dynamics in the Paroxysmal Supraventricular Tachycardia market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current market valuation of the Paroxysmal Supraventricular Tachycardia Market?**
A: The market valuation was 299.29 USD Million in 2024.

**Q: What is the projected market size for the Paroxysmal Supraventricular Tachycardia Market by 2035?**
A: The projected valuation for 2035 is 622.88 USD Million.

**Q: What is the expected CAGR for the Paroxysmal Supraventricular Tachycardia Market during the forecast period?**
A: The expected CAGR during 2025 - 2035 is 6.89%.

**Q: Which companies are considered key players in the Paroxysmal Supraventricular Tachycardia Market?**
A: Key players include Abbott Laboratories, Medtronic, Boston Scientific, and Johnson & Johnson.

**Q: What are the primary types of Paroxysmal Supraventricular Tachycardia and their market values?**
A: Atrioventricular Nodal Reentrant Tachycardia had a market value range of 75.0 to 150.0 USD Million.

**Q: How does the market for Catheter Ablation compare to other treatment approaches?**
A: Catheter Ablation had a market value range of 100.0 to 250.0 USD Million, indicating strong demand.

**Q: What demographic factors influence the Paroxysmal Supraventricular Tachycardia Market?**
A: Factors such as age group and comorbid conditions had market values of 75.0 to 150.0 USD Million and 90.0 to 180.0 USD Million, respectively.

**Q: What diagnostic methods are utilized in the Paroxysmal Supraventricular Tachycardia Market?**
A: Electrocardiogram was the leading diagnostic method with a market value range of 120.0 to 250.0 USD Million.

**Q: What treatment approaches are available for Paroxysmal Supraventricular Tachycardia?**
A: Available treatment approaches include Medication, Catheter Ablation, and Electrical Cardioversion, with respective market values.

**Q: How do lifestyle factors impact the Paroxysmal Supraventricular Tachycardia Market?**
A: Lifestyle factors had a market value range of 74.29 to 172.88 USD Million, suggesting their relevance in patient management.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/paroxysmal-supraventricular-tachycardia-market-5918*